Healthcare
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(SFOSF)
Live Price
Offline$2.02
+0.00% today
1Y Change
+3.32%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $65.69B
- Revenue Growth
- -1.6%
- EPS Growth
- +21.2%
- Dividend Yield
- 1.3%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) is a Healthcare stock with a market cap of $65.69B and listed on OTC. The stock last traded around $2.02 and up 3.3% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of +21.2%, a dividend yield of 1.3%. What stands out right now is revenue -1.6%, EPS +21.2%, free cash flow +1045.0% with operating margin 9.6% and ROIC 3.1%. The dividend is present but secondary, with a yield around 1.3%. Valuation is more restrained than many high-expectation growth names at P/E 18.9 and price/sales 1.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SFOSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.6% vs +7.6% peer median
Operating Margin
Below sector median
+9.6% vs +19.4% peer median
P/E
Below sector median
18.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.6% and EPS is at +21.2%, with operating margin around 9.6%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 27, 2026 | โ | +0.0% | +0.0% | -16.3% |
2026 Mar 25, 2026 | +113.0% | +0.0% | -0.4% | -4.1% |
2025 Oct 29, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SFOSF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SFOSF Max Drawdown
-42.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SFOSF and SPY.
Company Overview
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Other OTC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
- Leadership
- Yi Liu
- IPO Date
- Apr 21, 2014
- Employees
- 40.6k
- Street Address
- Building A
- Mailing
- Shanghai, 200233
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 3398 7000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.9
- EV/EBITDA
- 16.2
- Price/Sales
- 1.6
- Price/Book
- 1.3
Growth
- Revenue
- -1.6%
- EPS
- +21.2%
- Free Cash Flow
- +1045.0%
Profitability
- Gross Margin
- 49.4%
- Operating Margin
- 9.6%
- Net Margin
- 8.2%
- ROE
- 7.2%
- ROIC
- 3.1%
Balance Sheet
- Debt/Equity
- 0.81
- Current Ratio
- 0.93
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.